<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385928</url>
  </required_header>
  <id_info>
    <org_study_id>NTA1702</org_study_id>
    <nct_id>NCT03385928</nct_id>
  </id_info>
  <brief_title>STOP-MSU: Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - in a Mobile Stroke Unit</brief_title>
  <official_title>STOP-MSU: Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - in a Mobile Stroke Unit. A Phase II Randomised, Placebo-controlled, Investigator-driven Trial of Tranexamic Acid Within 2 Hours of Intracerebral Haemorrhage Using a Mobile Stroke Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be prospective phase II randomised, double-blind, placebo-controlled,
      investigator-driven trial in acute intracerebral haemorrhage patients.

      The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo
      and will test the hypothesis that ICH (intracranial haemorrhage) patients treated with
      intravenous tranexamic acid within 2 hours of symptom onset will have lower rates of
      haematoma growth than compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will include patients with acute spontaneous ICH, who are ≥18 years of age and are
      eligible for treatment within 2 hours of stroke onset. A sample size of 62 patients is
      calculated to give 80% power to detect a large effect size assuming mean relative ICH
      haematoma growth of 38% in the placebo arm compared to 19% in the active treatment arm and
      standard deviation of 19%, inflated for nonparametric analysis. Standard CT for initial
      diagnosis of suspected stroke patients will be performed to MSU protocols. Neurological
      impairment and functional scores will be measured by a neurologist or health care
      professional trained in their administration. The assessors will be blinded to the treatment
      group. Patients eligible for the RCT will be randomised in a 1:1 ratio to receive either
      Tranexamic acid or placebo according to a centralised web-based procedure utilising randomly
      permuted blocks of random size.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be prospective phase II randomised, double-blind, placebo-controlled investigator-driven trial in acute intracerebral haemorrhage patients.
The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative ICH haematoma growth at 24±3 hours, adjusted for baseline ICH volume (mls)</measure>
    <time_frame>24 hours(plus or minus 3 hours)</time_frame>
    <description>Relative ICH haematoma growth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICH growth</measure>
    <time_frame>24 hours (plus or minus 3 hours)</time_frame>
    <description>ICH growth as defined by either 33% or 6ml increase from baseline, adjusted for baseline ICH volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute ICH growth (mls)</measure>
    <time_frame>24 hours (plus or minus 3 hours)</time_frame>
    <description>Absolute ICH growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative ICH growth volume (mls)</measure>
    <time_frame>1 hour after baseline CT</time_frame>
    <description>Relative and absolute ICH growth volume, adjusted for baseline ICH volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major thromboembolic events</measure>
    <time_frame>3 months</time_frame>
    <description>Major thromboembolic events (myocardial infarction, ischaemic stroke, pulmonary embolism) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular haematoma growth</measure>
    <time_frame>24 hours (plus or minus 3 hours)</time_frame>
    <description>Absolute intraventricular haematoma (IVH) growth volume adjusted for baseline IVH volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>3 months</time_frame>
    <description>mRS 0-4 or back to pre-stroke level, or mRS 0-3 or back to pre-stroke level (with lowest mRS score being the better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>3 months</time_frame>
    <description>Categorical shift in mRS (0-6 with 6 being worst outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Intracerebral Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mls intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Investigational product given within 2 hours of symptom onset</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo given within 2 hours of symptom onset</description>
    <arm_group_label>Normal Saline (0.9% NaCl)</arm_group_label>
    <other_name>0.9%NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with an acute ICH

          2. Age ≥18 years

          3. Treatment can commence within 2 hours of symptom onset (or in patients with unknown
             time of symptom onset, the time patient was last known to be well)

          4. Consent can be obtained from participant or person responsible. When emergency
             treatment procedures have been followed the participant or person responsible will be
             asked for consent to continue in the study.

        Exclusion Criteria:

          1. Glasgow coma scale (GCS) total score of &lt;8

          2. Brainstem ICH

          3. ICH volume &gt;70 ml as measured by the ABC/2 method

          4. ICH known or suspected by study investigator to be secondary to trauma, aneurysm,
             vascular malformation, haemorrhagic transformation of ischaemic stroke, cerebral
             venous thrombosis, thrombolytic therapy, tumour, or infection

          5. Any history or current evidence suggestive of venous or arterial thrombotic events
             within the previous 12 months, including clinical, ECG, laboratory, or imaging
             findings. Clinically silent chance findings of old ischemia are not considered
             exclusion.

          6. Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency.

          7. Use of heparin, low-molecular weight heparin, GPIIb/IIIa antagonist, or oral
             anticoagulation (e.g. warfarin, factor Xa inhibitor, thrombin inhibitor) within the
             previous 14 days, irrespective of laboratory values

          8. Pregnancy (women of childbearing potential must be tested)

          9. Planned surgery for ICH within 24 hours

         10. Concurrent or planned treatment with haemostatic agents (e.g. prothrombin complex
             concentrate, vitamin K, fresh frozen plasma, or platelet transfusion)

         11. Participation in any investigational study in the last 30 days

         12. Known terminal illness or planned withdrawal of care or comfort care measures

         13. Any condition that, in the judgment of the investigator could impose hazards to the
             patient if study therapy is initiated or affect the participation of the patient in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Donnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Florey Institute of Neuroscience and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health Dept of Neurology &amp; The University of Melbourne Dept of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health Dept of Neurology &amp; The University of Melbourne Dept of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry Zhao, MD</last_name>
    <phone>+61 3 9342 7000</phone>
    <email>henry.zhao@mh.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Sallaberger</last_name>
    <phone>0438 471 423</phone>
    <email>michele.sallaberger@florey.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Davis</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICH</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Antifibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Hematologic Agents</keyword>
  <keyword>Hemostatics</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Angiography</keyword>
  <keyword>Cerebral Angiography</keyword>
  <keyword>Tomography, X-Ray Computed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

